Bacteremia with ESBL-producing Enterobacterales is associated with IgG antibodies reacting with CTX-M-15 and/or CTX-M-27

Int J Med Microbiol. 2020 Dec;310(8):151468. doi: 10.1016/j.ijmm.2020.151468. Epub 2020 Dec 1.

Abstract

Objectives: The adaptive humoral immune response following clinical infection with extended spectrum beta-lactamase (ESBL)-producing Enterobacterales (EPE) has not been thoroughly investigated. The aim of this study was to investigate the presence of anti-CTX-M-15 and/or anti-CTX-M-27 IgG antibodies in bacteremia patients diagnosed with EPE compared to a control group consisting of patients suffering from bacteremia with third generation cephalosporin-susceptible Escherichia coli (3GCSE).

Methods: Patientswith EPE (n = 59) or 3GCSE (n = 42) bacteremia were recruited in this case control study in the Skåne County (South of Sweden). Sera were collected 1-26 months after bacteremia. Enzyme-linked immunosorbent assay (ELISA) was used for detection of specific IgG antibodies directed against recombinant beta-lactamases CTX-M-15 and CTX-M-27. The beta-lactamase resistance genes of the corresponding EPE blood isolates were determined by DNA sequencing.

Results: The majority (n = 47; 80 %) of the 59 EPE blood isolates carried blaCTX-M-15 or blaCTX-M-27 genes. IgG antibodies reacting to the corresponding CTX-M enzyme was seen in 28 % (13/47) of patients suffering from EPE-bacteremia, while antibodies were detected in only 9.5 % (4/42) of patients with 3GCSE (p = 0.03). Patients with EPE had a statistically significantly higher median Charlson comorbidity index and prevalence of renal disease (p = 0.01), compared to the 3GCSE control group.

Conclusion: This study implies that EPE bacteremia can trigger production of IgG antibodies targeting ESBL. Further investigations are required to determine the functional role of anti-ESBL antibodies against EPE bacteremia.

Keywords: Antimicrobial resistance; Beta-Lactamases; CTX; Escherichia coli; Immune response; Immunoglobulin.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Bacterial / immunology*
  • Bacteremia / immunology*
  • Case-Control Studies
  • Escherichia coli Infections / drug therapy
  • Escherichia coli Infections / immunology*
  • Humans
  • Immunoglobulin G / immunology*
  • Sweden
  • beta-Lactamases / genetics
  • beta-Lactamases / immunology*

Substances

  • Anti-Bacterial Agents
  • Antibodies, Bacterial
  • Immunoglobulin G
  • beta-Lactamases